GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » 3-Year ROIIC %

Invitae (Invitae) 3-Year ROIIC % : -49.74% (As of Dec. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Invitae 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Invitae's 3-Year ROIIC % for the quarter that ended in Dec. 2022 was -49.74%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Invitae's 3-Year ROIIC % or its related term are showing as below:

NVTAQ's 3-Year ROIIC % is ranked worse than
75.58% of 217 companies
in the Medical Diagnostics & Research industry
Industry Median: -8.16 vs NVTAQ: -49.74

Invitae 3-Year ROIIC % Historical Data

The historical data trend for Invitae's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae 3-Year ROIIC % Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.48 -35.37 -13.21 -16.03 -49.74

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -49.74 - - -

Competitive Comparison of Invitae's 3-Year ROIIC %

For the Diagnostics & Research subindustry, Invitae's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's 3-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Invitae's 3-Year ROIIC % falls into.



Invitae 3-Year ROIIC % Calculation

Invitae's 3-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -704.0938488 (Dec. 2022) - -226.729446 (Dec. 2019) )/( 1354.108 (Dec. 2022) - 394.357 (Dec. 2019) )
=-477.3644028/959.751
=-49.74%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Invitae  (OTCPK:NVTAQ) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Invitae 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Invitae's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301